- Home
- MKTW vs NRXS Comparison
MKTW vs NRXS Comparison
Compare MKTW & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MKTW
- NRXS
- Stock Information
- Founded
- MKTW 1999
- NRXS 2011
- Country
- MKTW United States
- NRXS United States
- Employees
- MKTW N/A
- NRXS N/A
- Industry
- MKTW Computer Software: Prepackaged Software
- NRXS
- Sector
- MKTW Technology
- NRXS
- Exchange
- MKTW Nasdaq
- NRXS Nasdaq
- Market Cap
- MKTW 23.1M
- NRXS 20.3M
- IPO Year
- MKTW N/A
- NRXS 2023
- Fundamental
- Price
- MKTW $0.50
- NRXS $3.15
- Analyst Decision
- MKTW Buy
- NRXS
- Analyst Count
- MKTW 2
- NRXS 0
- Target Price
- MKTW $2.50
- NRXS N/A
- AVG Volume (30 Days)
- MKTW 1.3M
- NRXS 23.3K
- Earning Date
- MKTW 11-07-2024
- NRXS 11-12-2024
- Dividend Yield
- MKTW 8.01%
- NRXS N/A
- EPS Growth
- MKTW N/A
- NRXS N/A
- EPS
- MKTW 0.13
- NRXS N/A
- Revenue
- MKTW $423,378,000.00
- NRXS $2,456,219.00
- Revenue This Year
- MKTW N/A
- NRXS $383.16
- Revenue Next Year
- MKTW N/A
- NRXS N/A
- P/E Ratio
- MKTW $3.74
- NRXS N/A
- Revenue Growth
- MKTW N/A
- NRXS N/A
- 52 Week Low
- MKTW $0.47
- NRXS $2.00
- 52 Week High
- MKTW $3.62
- NRXS $3.89
- Technical
- Relative Strength Index (RSI)
- MKTW 37.90
- NRXS 59.42
- Support Level
- MKTW $0.47
- NRXS $2.25
- Resistance Level
- MKTW $0.70
- NRXS $3.78
- Average True Range (ATR)
- MKTW 0.06
- NRXS 0.42
- MACD
- MKTW -0.01
- NRXS 0.07
- Stochastic Oscillator
- MKTW 14.60
- NRXS 63.58
About MKTW MarketWise Inc.
Marketwise Inc is a multi-brand subscription services platform providing premium financial research, software, education, and tools for investors. Its products are built for high-value financial research, education, actionable investment ideas and investment software. It is a digital, direct-to-consumer company offering its research across a variety of platforms including mobile, desktops, and tablets.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).